GEN-MKT-18-7897-A
Jul 14, 2017 | Blogs, Food / Beverage | 0 comments
Don’t judge a nutritional supplement by its label, as often, government monitoring of ingredients begins after the product enters the consumer market1. Meanwhile, there may be additional additives not mentioned on the label as they are used to address supplement side effects. Such is the case in the United States where even though federal law requires supplements to carry a dietary supplement label or a substitutional term, monitoring begins once a supplement is on the market. In China meanwhile, the China Food and Drug Administration’s (CFDA) health product potential illegal additives list, clearly stipulates monitoring processes for additives in six different types of nutritional supplements including weight loss, blood sugar reduction, blood pressure reduction, anti-fatigue, sleep improvement and immune strengthening functions.Read Tech Note >
Keeping up with additives is no small job for the labs tasked with analysis. A research report by Grand View Research notes that “The rising sales of sports nutrition products in the U.S. and China along with new product launches are likely to have a significant impact on the industry. The market is expected to generate revenues worth USD 37.16 billion by 2024.2
Since drug interactions can be unclear, however, they continue to merit clarity. In the following application note, Use of X500R QTOF for Monitoring Unexpected Additives in Nutritional Supplements, researchers used the X500R QTOF high-resolution mass spectrometry and SCIEX OS software for quick and qualitative confirmation of 50 additives. Want to see how your lab can keep up with supplemental screening? Download the tech note to discover how you can overcome matrix interference in complex matrices for the accurate testing of additives such as atenolol, nitrendipine, nifedipine, glibenclamide, glipizide, rosiglitazone, and gliclazide.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network